Table 2.
Univariate analysis for selection of predictors of early biochemical remission, long-term remission and relapse
| Early biochemical remission | Long-term remission | Relapse | |
|---|---|---|---|
| Sex | — | — | — |
| Age at diagnosis (years) | Older* | Older** | Younger* |
| Age at surgery (years) | Older* | Older** | Younger* |
| Nadir GH at diagnosis (µg/L) | ↓ nadir GH* | ↓ nadir GH** | ↑ nadir GHa |
| GH at diagnosis (µg/L) | ↓ GH** | ↓ GH** | ↑ GH* |
| IGF-1 at diagnosis (× ULN) | ↓ IGF-1** | ↓ IGF-1a | — |
| Tumor size (micro/macro) | Micro*** | Micro*** | Macro* |
| Maximum tumor diameter (mm) | Smaller *** | Smaller *** | Larger *** |
| Cavernous sinus invasion | No CSI** | No CSI*** | — |
| Preoperative medical treatment | |||
| DA | — | — | — |
| SSA-1 | Yesa | Yesa | — |
| SSA-2 | — | — | — |
| GHRA | — | — | — |
Abbreviations: CSI, cavernous sinus invasion; DA, dopamine agonist; GH, growth hormone; GHRA, growth hormone receptor antagonist (ie, pegvisomant); IGF-1, insulin-like growth factor 1; SSA-1, first-generation somatostatin analog (ie, lanreotide or octreotide); SSA-2, second-generation somatostatin analog (ie, pasireotide); ULN, upper limit of normal.
*P < .05; **P < .01; *** P < .0001.
a Trend towards significance at P < .20.